Amicus Therapeutics Stock Debt To Equity
| FOLD Stock | USD 9.98 0.02 0.20% |
Amicus Therapeutics fundamentals help investors to digest information that contributes to Amicus Therapeutics' financial success or failures. It also enables traders to predict the movement of Amicus Stock. The fundamental analysis module provides a way to measure Amicus Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Amicus Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Debt To Equity | 2.47 | 2.60 |
Amicus | Debt To Equity |
Amicus Therapeutics Company Debt To Equity Analysis
Amicus Therapeutics' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Amicus Therapeutics Debt To Equity | 2.60 % |
Most of Amicus Therapeutics' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Amicus Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Amicus Debt To Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Amicus Therapeutics is extremely important. It helps to project a fair market value of Amicus Stock properly, considering its historical fundamentals such as Debt To Equity. Since Amicus Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Amicus Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Amicus Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
Amicus Total Stockholder Equity
Total Stockholder Equity |
|
According to the company disclosure, Amicus Therapeutics has a Debt To Equity of 2.6%. This is 95.14% lower than that of the Biotechnology sector and 86.57% lower than that of the Health Care industry. The debt to equity for all United States stocks is 94.66% higher than that of the company.
Amicus Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Amicus Therapeutics' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Amicus Therapeutics could also be used in its relative valuation, which is a method of valuing Amicus Therapeutics by comparing valuation metrics of similar companies.Amicus Therapeutics is currently under evaluation in debt to equity category among its peers.
Amicus Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Amicus Therapeutics from analyzing Amicus Therapeutics' financial statements. These drivers represent accounts that assess Amicus Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Amicus Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.3B | 6.0B | 3.1B | 3.5B | 4.2B | 4.4B | |
| Enterprise Value | 2.4B | 6.3B | 3.3B | 3.8B | 4.4B | 4.6B |
Amicus Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Amicus Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Amicus Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Amicus Fundamentals
| Return On Equity | -0.67 | ||||
| Return On Asset | 0.0116 | ||||
| Profit Margin | (0.21) % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 3.17 B | ||||
| Shares Outstanding | 298.81 M | ||||
| Shares Owned By Insiders | 0.73 % | ||||
| Shares Owned By Institutions | 99.27 % | ||||
| Number Of Shares Shorted | 21 M | ||||
| Price To Earning | (9.18) X | ||||
| Price To Book | 16.64 X | ||||
| Price To Sales | 6.04 X | ||||
| Revenue | 399.36 M | ||||
| Gross Profit | 290.63 M | ||||
| EBITDA | (92.08 M) | ||||
| Net Income | (151.58 M) | ||||
| Cash And Equivalents | 386.84 M | ||||
| Cash Per Share | 1.38 X | ||||
| Total Debt | 445.06 M | ||||
| Debt To Equity | 2.60 % | ||||
| Current Ratio | 3.02 X | ||||
| Book Value Per Share | 0.60 X | ||||
| Cash Flow From Operations | (69.09 M) | ||||
| Short Ratio | 7.28 X | ||||
| Earnings Per Share | (0.34) X | ||||
| Price To Earnings To Growth | (0.18) X | ||||
| Target Price | 17.75 | ||||
| Number Of Employees | 500 | ||||
| Beta | 0.67 | ||||
| Market Capitalization | 2.98 B | ||||
| Total Asset | 777.88 M | ||||
| Retained Earnings | (2.68 B) | ||||
| Working Capital | 315.37 M | ||||
| Current Asset | 216.6 M | ||||
| Current Liabilities | 73.62 M | ||||
| Net Asset | 777.88 M |
About Amicus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Amicus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amicus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amicus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports:Check out Amicus Therapeutics Piotroski F Score and Amicus Therapeutics Altman Z Score analysis. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.34) | Revenue Per Share 1.629 | Quarterly Revenue Growth 0.367 | Return On Assets 0.0116 | Return On Equity (0.67) |
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.